Micro Therapeutics' Onyx(R) Demonstrated in Live Cases to Clinicians At LINC 2001.
IRVINE, Calif., Oct. 17 /PRNewswire/ --
Micro Therapeutics, Inc. (Nasdaq: MTIX MTIX Moving Target Information Exploitation
MTIX Moving Target Indicator Exploitation
MTIX MetroTix, Inc. (Saint Louis, MO, USA) ) today said its flagship product, Onyx(R), an innovative treatment for conditions that can lead to stroke, and related products were presented and demonstrated in two successful live cases to leading interventional neuroradiologists from around the world at LINC 2001 in Paris, France.
LINC is a three-day endovascular neuroradiology neuroradiology /neu·ro·ra·di·ol·o·gy/ (-ra?de-ol´ah-je) radiology of the nervous system.
1. The branch of radiology that deals with the nervous system. workshop organized by Professor Jacques Moret, chief of interventional neuroradiology at the Foundation Rothschild in Paris, that provides participants a unique opportunity to view live clinical demonstrations of the latest procedures and state-of-the-art devices for neuro-intervention. A team led by Prof. Moret utilized Onyx in two cases, and debuted the newest generation of several Micro Therapeutics (MTI MTI Ministry of Trade and Industry (Singapore)
MTI Metal Treating Institute
MTI Moving Target Indicator (radar)
MTI Magyar Távirati Iroda (news agency in Budapest, Hungary) ) products, including micro catheters, guidewires and occlusion balloons.
"LINC provides practitioners of endovascular neuroradiology the most current products, procedures and research," said John Rush, Micro Therapeutic's president and chief executive officer. "MTI is a leading developer of medical devices in this emerging area, and I was pleased Prof. Moret was able to showcase several of MTI's' recent introductions."
The first case performed by Prof. Moret's team involved a large aneurysm in the carotid artery. Despite tortuous anatomy, the team was able to access the aneurysm site with MTI's new X-pedion(TM) Guidewire, and successfully fill the aneurysm with Onyx using MTI's Rebar Micro Catheter and new HyperGlide Balloon. In the second case, a massive arteriovenous malformation (AVM AVM 1 Acute viral meningitis, see there 2 Arteriovenous malformation, see there ) in the brain was successfully embolized using Onyx with MTI's new UltraFlow Flow Directed Catheter.
Onyx is a liquid embolic material that is delivered through MTI's proprietary micro catheters directly into a targeted vascular malformation, such as a brain aneurysm or AVM. Once inside the targeted malformation malformation /mal·for·ma·tion/ (-for-ma´shun)
1. a type of anomaly.
2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process. , the liquid quickly transforms into a spongy polymer mass designed to seal off the malformation from blood flow. Onyx is non-adhesive, which enhances controllability during delivery, and it is visible under fluoroscopy fluoroscopy /flu·o·ros·co·py/ (fldbobr-ros´kah-pe) examination by means of the fluoroscope.
Examination by means of a fluoroscope. Also called radioscopy. -- allowing clinicians a clear view of the embolization procedure in real-time.
In Europe, MTI has received CE Mark to commercially promote Onyx for use in the treatment of aneurysms, AVMs and certain peripheral applications. In the U.S., the company is conducting pivotal clinical trials that are studying the use of Onyx in the treatment of aneurysms and AVMs. Worldwide, across all therapies, Onyx has been used in more than 1,300 procedures.
Statements contained in this press release which are not historical information, are forward-looking statements as defined within the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties include, but are not limited to, in no particular order: the company's ability to build a sales force in Europe, the impact of terminating its distribution agreement with Guidant Corporation, product development, risks and results of clinical testing, demand and market acceptance risks, the impact of competitive products and pricing, regulatory approval and future product development. More detailed information on these and additional factors which could affect Micro Therapeutics, Inc.'s operating and financial results are described in the company's prospectus dated February 18, 1997, as well as in its Forms 10-QSB, 10-KSB and other reports, filed or to be filed with the Securities and Exchange Commission. Micro Therapeutics, Inc. urges all interested parties to read these reports to gain a better understanding of the many business and other risks that the company faces. Additionally, Micro Therapeutics, Inc. undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.
MAKE YOUR OPINION COUNT - Click Here